FENC (Fennec Pharmaceuticals Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by FENC officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-01 | Rosty Raykov | — | MIXED | — | — |
| 2026-08-31 | Robert Andrade | CHIEF FINANCIAL OFFICER | A | — | — |
| 2026-08-31 | Pierre Sargis Sayad | Chief Medical Officer | MIXED | — | — |
| 2026-08-31 | Christiana Marie Cioffi | Chief Strategy Officer | A | — | — |
| 2026-08-31 | Terry L Evans | Chief Commercial Officer | A | — | — |
| 2026-08-31 | Jeffrey S. Hackman | Chief Executive Officer | A | — | — |
| 2026-08-28 | Robert Andrade | CHIEF FINANCIAL OFFICER | MIXED | — | — |
| 2026-08-04 | Rosty Raykov | — | Sell | — | — |
| 2026-08-03 | Rosty Raykov | — | A | — | — |
| 2026-08-03 | Christiana Marie Cioffi | Chief Strategy Officer | A | — | — |
| 2026-08-03 | Terry L Evans | Chief Commercial Officer | A | — | — |
| 2026-08-03 | Robert Andrade | CHIEF FINANCIAL OFFICER | A | — | — |
| 2026-08-03 | Jeffrey S. Hackman | Chief Executive Officer | A | — | — |
| 2026-08-03 | Pierre Sargis Sayad | Chief Medical Officer | A | — | — |
| 2026-07-02 | Rosty Raykov | — | MIXED | — | — |
| 2026-07-01 | Terry L Evans | Chief Commercial Officer | A | — | — |
| 2026-07-01 | Jeffrey S. Hackman | Chief Executive Officer | A | — | — |
| 2026-07-01 | Robert Andrade | CHIEF FINANCIAL OFFICER | A | — | — |
| 2026-07-01 | Christiana Marie Cioffi | Chief Strategy Officer | A | — | — |
| 2026-07-01 | Pierre Sargis Sayad | Chief Medical Officer | A | — | — |
| 2026-06-10 | Khalid Islam | Director | A | — | — |
| 2026-06-10 | Jodi A Cook | Director | A | — | — |
| 2026-06-10 | CHRIS A RALLIS | Director | A | — | — |
| 2026-06-10 | Marco Maria Brughera | Director | A | — | — |
| 2026-06-02 | Rosty Raykov | Director | MIXED | — | — |
| 2026-06-01 | Terry L Evans | Chief Commercial Officer | A | — | — |
| 2026-06-01 | Robert Andrade | CHIEF FINANCIAL OFFICER | A | — | — |
| 2026-06-01 | Pierre Sargis Sayad | Chief Medical Officer | A | — | — |
| 2026-06-01 | Christiana Marie Cioffi | Chief Strategy Officer | A | — | — |
| 2026-06-01 | Jeffrey S. Hackman | Chief Executive Officer | A | — | — |
| 2026-05-12 | CHRIS A RALLIS | Director | MIXED | — | — |
| 2026-05-01 | Terry L Evans | Chief Commercial Officer | M | — | — |
| 2026-05-01 | Robert Andrade | CHIEF FINANCIAL OFFICER | M | — | — |
| 2026-05-01 | Christiana Marie Cioffi | Chief Strategy Officer | M | — | — |
| 2026-05-01 | Pierre Sargis Sayad | Chief Medical Officer | M | — | — |
| 2026-05-01 | Jeffrey S. Hackman | Chief Executive Officer | M | — | — |
| 2026-05-01 | Rosty Raykov | Director | MIXED | — | — |
| 2026-04-02 | Terry L Evans | Chief Commercial Officer | M | — | — |
| 2026-04-02 | Pierre Sargis Sayad | Chief Medical Officer | M | — | — |
| 2026-04-02 | Rosty Raykov | Director | MIXED | — | — |
| 2026-04-02 | Robert Andrade | CHIEF FINANCIAL OFFICER | M | — | — |
| 2026-04-02 | Jeffrey S. Hackman | Chief Executive Officer | M | — | — |
| 2026-04-02 | Christiana Marie Cioffi | Chief Strategy Officer | M | — | — |
| 2026-03-26 | Robert Andrade | CHIEF FINANCIAL OFFICER | M | — | — |
| 2026-03-26 | Christiana Marie Cioffi | Chief Strategy Officer | M | — | — |
| 2026-03-03 | Robert Andrade | CHIEF FINANCIAL OFFICER | A | — | — |
| 2026-03-03 | Rosty Raykov | Director | MIXED | — | — |
| 2026-02-19 | Jeffrey S. Hackman | Chief Executive Officer | M | — | — |
| 2026-02-19 | Robert Andrade | CHIEF FINANCIAL OFFICER | M | — | — |
| 2026-02-02 | Robert Andrade | CHIEF FINANCIAL OFFICER | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 3,993,694 | — |
| — | 10%+ Owner | 3,754,081 | — |
| — | 10%+ Owner | 3,744,741 | — |
| — | 10%+ Owner | 3,586,531 | — |
| — | 10%+ Owner | 3,435,731 | — |
| — | 10%+ Owner | 3,317,271 | — |
| — | 10%+ Owner | 2,744,741 | — |
| — | CHIEF FINANCIAL OFFICER | 241,306 | — |
| — | Director | 143,333 | — |
| — | Director | 124,411 | — |
| — | Chief Executive Officer | 66,302 | — |
| — | Director | 63,077 | — |
| — | Chief Strategy Officer | 24,644 | — |
| — | CHIEF OPERATING OFFICER | 22,222 | — |
| — | Chief Commercial Officer | 21,519 | — |
| — | Chief Medical Officer | 9,519 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the FENC quote page; the site-wide leaderboard is on the insider transactions hub.